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Abstract: The emergence of bacterial resistance to the major classes of antibiotics has become a serious
problem over recent years. For aminoglycosides, the major biochemical mechanism for bacterial resistance
is the enzymatic modification of the drug. Interestingly, in several cases, the oligosaccharide conformation
recognized by the ribosomic RNA and the enzymes responsible for the antibiotic inactivation is remarkably
different. This observation suggests a possible structure-based chemical strategy to overcome bacterial
resistance; in principle, it should be possible to design a conformationally locked oligosaccharide that still
retains antibiotic activity but that is not susceptible to enzymatic inactivation. To explore the scope and
limitations of this strategy, we have synthesized several aminoglycoside derivatives locked in the ribosome-
bound “bioactive” conformation. The effect of the structural preorganization on RNA binding, together with
its influence on the aminoglycoside inactivation by several enzymes involved in bacterial resistance, has
been studied. Our results indicate that the conformational constraint has a modest effect on their interaction
with ribosomal RNA. In contrast, it may display a large impact on their enzymatic inactivation. Thus, the
work presented herein provides a key example of how the conformational differences exhibited by these
ligands within the binding pockets of the ribosome and of those enzymes involved in bacterial resistance
can, in favorable cases, be exploited for designing new antibiotic derivatives with improved activity in resistant
strains.
Introduction
Aminoglycoside antibiotics are highly potent, wide-spectrum
bactericidals.1-4 These drugs bind to the decoding region
aminoacyl-tRNA site (A-site) inducing codon misreading and
inhibiting translocation, eventually resulting in cell death.1-4
From a chemical point of view, aminoglycosides are poly-
cationic oligosaccharides carrying several hydroxyl and amino
functional groups. Most include one or more amino sugars
attached to a 2-deoxystreptamine ring (ring II in Scheme 1).
The structures of several aminoglycosides, such as gentamycin,
tobramycin, and paromomycin, bound to the target ribosomal
A-site RNA have been determined recently by both X-ray and
NMR methods.5-7 These structures have provided an extremely
detailed knowledge about the interactions that stabilize the drug/
RNA complexes.
Several years after the introduction of aminoglycosides in
human antibacterial chemotherapy, resistant organisms began
to appear. Indeed, the emergence of bacterial resistance to the
major classes of antibiotics has become a serious problem over
recent years.8,9 Acquired resistance to aminoglycoside antibiotics
can occur via three different mechanisms: mutation of the
ribosomal target, reduced permeability for the antibiotics, and
enzymatic modification of the drugs, thus leading to inactivation.
The most prevalent source of clinically relevant resistance is
conferred by the third mechanism, the enzymatic inactivation
of the drugs.8,9 Enzymes involved in bacterial defense against
aminoglycoside antibiotics can be broadly classified as N-
acetyltransferases (AACs), O-adenyl transferases (ANTs), and† Instituto de Quı´mica Orga´nica General (CSIC), Madrid 28006, Spain.
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O-phosphotransferases (APHs). It is evident that a detailed
knowledge of the structures of these enzymes and their
interactions with the drugs should provide a framework that
will facilitate the rational design either of novel aminoglycosides,
not susceptible to modification, or of inhibitors of these
enzymes, which could be administered in tandem with existing
aminoglycosides. Indeed, the search for new derivatives not
susceptible to modification by bacterial defense proteins con-
stitutes an active field of research.10-13
The 3D structures of several aminoglycoside-enzyme com-
plexes have been described recently by X-ray methods.9,14
Interestingly, in some cases, the 3D structure of the antibiotic
in the enzyme binding site significantly differs from that
observed in the corresponding aminoglycoside/A-site RNA
complex (see Scheme 1). For example, Staphylococcus aureus
ANT(4′) selects a high energy conformation of the ligand,
kanamycin.15 In particular, the GlcR(1-4)-2-deoxy streptamine
fragment (numbered as units I and II in Scheme 1), present in
all aminoglycosides with different patterns of amination/
hydroxylation at the glucose unit (I), adopts an anti-¾ geometry
(…/¾, -21/151). In contrast, for tobramycin and paromomycin,
the analogous glycosidic linkage is defined by a syn-¾ confor-
mation (…/¾  -40/-30) in the RNA-bound state. The “syn-
¾” geometry also constitutes the most populated minimum for
the free antibiotics, according to NMR data.16 The drug confor-
mation selected by ANT(4′) represents a high-energy minimum
that must be stabilized by specific aminoglycoside-protein
interactions. In a similar way, the X-ray structure of Mycobac-
terium tuberculosis AAC(2′) in complex with ribostamycin
shows that the Ribâ(1-5)-2-deoxy streptamine fragment (num-
(10) (a) Kondo, S.; Iinuma, K.; Yamamoto, H.; Maeda, K.; Umezawa, H. J.
Antibiot. 1975, 26, 412-417. (b) Kondo, S.; Hotta, K. J. Infect. Chemother.
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Scheme 1. Schematic Representation of the Conformational Differences (Highlighted with a Dotted Box) Exhibited by Aminoglycosides in
the Binding Pockets of RNA and Some of the Enzymes Involved in Bacterial Resistancea
a The glucose, 2-deoxy-streptamine, and ribose units are numbered as I, II, and III, respectively. The values of the glycosidic torsion angles …(H1-
C1-Ox-Cx) and ¾(Hx-Cx-O1-C1) for each glycosidic linkage in the bound state, together with the pdb codes of the complexes, are indicated. The
position of the aminoglycoside modified by the enzyme is marked by an arrow. A schematic representation of the GlcR(1-4)2-deoxy-streptamine fragment
present in neomycin (X ) NH2, Y ) NH2, R ) 2,6-diamino-2,6-dideoxy-L-Idoâ(1-3)Rib, R′ ) H), paromomycin (X ) OH, Y ) NH2, R ) 2,6-diamino-
2,6-dideoxy-L-Idoâ(1-3)Rib, R′ ) H), ribostamycin (X ) NH2, Y ) NH2, R ) Rib, R′ ) H), and kanamycin (X ) NH2, Y ) OH, R ) H, R′ ) 3-amino-
3-deoxy-R-Glc) is shown in the top left-hand corner.
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bered as units III and II in Scheme 1) also adopts a high energy
“anti-¾” conformation (…/¾ ) 28/-173).17 This geometry is
significantly different to the bioactiVe “syn-ª” orientation
adopted by the same glycosidic bond in the paromomycin/A-
site complex.5,6 An additional key example of conformational
differences of aminoglycosides between the RNA- and protein-
bound states is provided by the recently reported structure of
the Salmonella enteritidis AAC(6′) in complex with ribosta-
mycin.18 In this case, the Ribâ(1-5)-2-deoxy streptamine
fragment (units III and II in Scheme 1) of the oligosaccharide
presents a rather unusual nonexo-anomeric conformation (char-
acterized by a … angle of -5°). In addition, the furanose ring
(numbered as III in Scheme 1) is bound in a C2-endo
conformation, in contrast with the C3-endo geometry selected
by the ribosomal RNA. A similar furanose puckering is also
recognized by the Enterococcus faecalis APH(3′) enzyme
according to the X-ray structure of its complex with neomycin-
B.19
The different 3D-shapes adopted by aminoglycosides in the
RNA- and enzyme-bound states suggest a possible structure-
based chemical strategy to obtain antibiotics with a better
activity against resistant bacteria. Assuming that, in these cases,
some degree of conformational distortion of the substrates is
required for enzymatic activity, it should be possible to design
a conformationally locked oligosaccharide that still retains
antibiotic activity but that is not susceptible to enzymatic
inactivation (Chart 1). 20
To test this hypothesis, we have designed and synthesized
several neomycin-B analogues locked in the RNA-bound
(bioactiVe) structure of the antibiotic.21 Thus, we have studied
the effect that structural preorganization has on the strength of
the aminoglycoside-RNA interaction. In a second step, we have
determined the susceptibility of the conformationally locked
derivatives to enzymatic inactivation, employing the enzymes
Staphylococcus aureus ANT(4′), Mycobacterium tuberculosis
AAC(2′), and Enterococcus faecalis APH(3′) as model systems.
The design of our conformationally constrained aminogly-
cosides is based on the structural information available for the
RNA-paromomycin complex.5,6 The structure of neomycin-B
(1) along with the numbering employed for the different sugar
units along this manuscript (I, II, III, and IV for the glucose,
2-deoxy-streptamine, ribose, and idose units, respectively) is
shown in Scheme 2. It is known that positions O5III and N2I
are hydrogen bonded within the ribosome bound state. Thus,
in our analogues, this interaction has been replaced by either a
direct covalent bond, as in 2, a two-methylene bridge, as in 3,
or by a salt bridge, as in 4 (see Scheme 2).
It should be pointed out that OH5III is involved in RNA
recognition5,6 and might also have an influence on the enzymatic
inactivation of the antibiotics. Since cyclization of neomycin-B
to give 2 or 3 required the removal of this OH group, the deoxy-
derivatives 5 and 6 were also synthesized as controls, to isolate
the effect of rigidification.
In the first part of the manuscript we present a detailed
description of the synthesis of the proposed neomycin-B
derivatives. The next section deals with the structural NMR
analysis of the obtained aminoglycosides. This study, essential
in order to establish any structure-activity relationship, shows
that, as expected, the obtained antibiotics exhibit a significantly
reduced flexibility with respect to natural neomycin-B and, in
addition, closely resemble its bioactive ribosome-bound con-
formation. In the next two sections the effect of the conforma-
tional restriction on the RNA binding properties and the
biological activity of these analogues is determined. Finally the
susceptibility of the obtained derivatives to enzymatic modifica-
tion has been tested employing three different enzymes involved
in bacterial resistance. This final analysis suggests that confor-
mational restriction might constitute a useful approach to prevent
aminoglycoside inactivation by bacterial defense proteins.
Results and Discussion
Synthesis of the Proposed Neomycin-B Derivatives.
A. Synthesis of Neomycin-B Conformationally Constrained
Analogue 2. Compound 2 was prepared following the simple
four-step procedure shown in Scheme 3. Thus, the hexa-N-
(benzyloxycarbonyl) derivative (7), readily prepared from
neomycin-B (1),22 was treated with 2,4,6-triisopropylbenzene-
sulfonyl chloride in pyridine23 to yield the primary sulfonate
(17) Vetting, M. W.; Hegde, S. S.; Javid-Majd, F.; Blanchard, J. S.; Roderick,
S. L. Nat. Struct. Biol. 2002, 9, 653-658.
(18) Vetting, M. W.; Magnet, S.; Nieves, E.; Roderick, S. L.; Blanchard, J. S.
Chem. Biol. 2004, 11, 565-573.
(19) Fong, D. H.; Berghuis, A. M. EMBO J. 2002, 21, 2323-2331.
(20) A key example of how the enzymatic activity can be modulated by small
conformational preferences of the substrates was reported recently: Galan,
M. C.; Venot, A. P.; Boons, G. J. Biochemistry 2003, 42, 8522-8529.
(21) A preliminary communication on some of the aspects described above has
been recently published: Asensio, J. L.; Hidalgo, A.; Bastida, A.; Torrado,
M.; Corzana, F.; Garcı´a-Junceda, E.; Can˜ada, J.; Chiara, J. L.; Jime´nez-
Barbero, J. J. Am. Chem. Soc. 2005, 127, 8278-8279.
(22) Kumar, V.; Remers, W. A. J. Org. Chem. 1981, 46, 4298-4300.
(23) Michael, K.; Wang, H.; Tor, Y. Bioorg. Med. Chem. 1999, 7, 1361-1372.
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(8), regioselectively. Deprotection of the amino groups by
palladium-catalyzed hydrogenolysis in MeOH/trifluoroacetic
acid gave crude sulfonate (9) that smoothly cyclized in a highly
regioselective way by mild heating in water at pH 7.0 to give
2 in 56% yield.
B. Synthesis of Neomycin-B Conformationally Con-
strained Analogue 3. The synthesis of compound 3 is shown
in Scheme 4. The key step involves a two-carbon atom
elongation of ring III side chain through a Wittig-type reaction
on aldehyde 12. The following four-step strategy was used to
obtain this aldehyde in good yield. First, regioselective protec-
tion of the primary hydroxyl group of 7, by treatment with
triisopropylsilyl trifluoromethanesulfonate and 2,6-lutidine, fol-
lowed by acetylation of the secondary hydroxyl groups gave
compound 10, which was desilylated by treatment with HFâ
pyridine to give 11. Finally, oxidation of 11 using the Dess-
Martin periodinane gave the required aldehyde 12 in 57% overall
yield from 7. Treatment of 12 with (methoxycarbonylmethylen)-
triphenylphosphorane in acetonitrile gave the corresponding R,â-
unsaturated ester 13, which was reduced with NaBH4 in the
presence of catalytic LiCl to give alcohol 14 in 89% yield.
Initially, we tried the selective activation of the primary alcohol
in 14, by treatment with 2,4,6-triisopropylbenzenesulfonyl
chloride in pyridine. However, the low regioselectivity obtained
in the reaction forced us to use a three-step strategy similar to
that described above. Thus, regioselective protection of the
primary hydroxyl group in 14 as a triisopropylsilyl ether, yielded
derivative 15. Acetylation of the secondary hydroxyl groups
followed by desilylation gave derivative 16, which was trans-
formed into the corresponding primary sulfonate by treatment
with p-toluenesulfonyl chloride in pyridine. Finally, clean
deacetylation of this derivative was best performed by mild
KCN-catalyzed methanolysis,24 to give 17. The carbamate
groups were removed by palladium-catalyzed hydrogenolysis
(24) Mori, K.; Tominaga, M.; Takigawa, T.; Matsui, M. Synthesis 1973, 790-
791.
Scheme 2. Schematic Representation of the Target Conformationally Locked Aminoglycosides (2-4) and the Deoxy Derivatives (5,6)a
a The numbering employed for the different sugar units is indicated for neomycin-B (compound 1).
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in MeOH/TFA. The resulting crude sulfonate was cyclized at
40 °C and pH 7.0 in H2O to give 3 in 62% yield.
The cyclization proceeded with an astonishing high regio-
selectivity considering the number of amino groups present in
this neomycin-B derivative (see Figure S1). In fact, compound
3 is the only macrocyclic derivative isolated from the reaction
mixture. Close inspection of the corresponding molecular model
shows that the two amino groups present in unit IV could also
participate in the nucleophilic attack to the side chain of III.
However, preliminary molecular mechanics calculations suggest
that the cyclization involving NH2 at position 2 of unit IV would
proceed through a high energy transition state. The preferred
cyclization through the NH2 at position 2 of ring I instead of
that at position 6 of unit IV can be explained considering the
different pKa values of these groups (7.4 vs 8.5, respec-
tively). In fact, under the employed experimental conditions (pH
7.0), the later amino group is fundamentally in its protonated
state.
Compound 6 was readily obtained from 17 by palladium-
catalyzed hydrogenolysis of the Cbz protecting groups and
subsequent reduction of the primary sulfonate under the same
conditions using a longer reaction time.
Finally derivatives 4 and 5 were easily obtained from 11 as
described in the Supporting Information.
NMR Analysis of the Conformationally Locked Amino-
glycosides 2-4. Selective 1D-NOE experiments were carried
out at 313 K and pH 5.0 for analogues 2-4. In addition, 3J
values were measured for all the sugar units (Table 1). To get
an experimentally derived ensemble, MD-tar (molecular dynam-
ics with time-averaged restraints) simulations25 were carried out
by including all the experimental NOE-derived distances and J
data as time-average restraints with the AMBER 5.026 program,
as described.16
The obtained trajectories were able to quantitatively reproduce
all the NMR experimental data. In all cases, the analyses of the
J couplings for units I and II unambiguously show that the 4C1
conformer is the very major one in water (>98%). In contrast,
for ring IV the 1C4 conformer with three axial and two equatorial
substituents is the only one experimentally detected. A similar
behavior has been reported for the natural antibiotic,16 and
therefore the cyclization of neomycin-B to give 2-3 does not
produce significant distortions in any of the three pyranose rings.
According to the experimental data, derivative 2 is extremely
rigid. Both J and NOE values (see Table 1 and Figure 1) are
consistent with a pure “gt” (öO-C4-C5-O5  60°) orientation
for the side chain of unit III and a unique puckering for its
furanose ring. In fact, only minor fluctuations around the I/II
and III/II glycosidic linkages are compatible with this macro-
cyclic structure, according to the MD-tar simulations.
A summary of the experimental data employed in the NMR
analysis of 3 is shown in Figure 2. In this case, a large number
of lower bound constraints had to be included in the MD-tar
simulations (together with the NOE derived distances and J
values) to properly define its structure in solution. As expected,
the experimental data indicates the presence of a larger degree
of flexibility. Thus, NOEs and J values are consistent with the
(25) Pearlman, D. A. J. Biomol. NMR 1994, 4, 1-16.
(26) Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T.
E.; DeBolt, S.; Ferguson, D.; Siebal, G.; Kollman, P. Comput. Phys.
Commun. 1995, 91, 1-41.
Scheme 3 a
a (a) CbzCl, Na2CO3, MeOH/H2O 3:1, 0 °C, 3 h, 92%; (b) 2,4,6-triisopropylbenzenesulfonyl chloride (TIBSCl), Py, rt, 72 h, 44%; (c) H2 (1 atm), Pd/C,
MeOH, trifluoroacetic acid, rt, 8 h, 90%; (d) H2O, pH 7.0, 60 °C, 5 d, 56%. In 7 and 8, R1 ) 2,6-diamino-2,6-di-N-(benzyloxycarbonyl)-2,6-dideoxy-â-
L-idose.
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presence of several orientations for the propylidene bridge that
links units I and III. For the side chain of ring III, a major
(>80%) “gt” (öO-C4-C5-C6  60°) and a minor (<20%) “gg”
(öO-C4-C5-C6  -60°) orientation are detected. Moreover, the
furanose ring presents two different puckerings characterized
by phase angles of 25° (“North”) and 160° (“South”) (for phase
angles the Altoona and Sundaralingan27 convention is employed)
and relative populations of 40:60, respectively. According to
the MD-tar trajectories, the macrocyclic structure present in 3
is compatible with relatively large fluctuations around the I/II
and III/II glycosidic linkages (see Figure 3).
Finally, our combined NMR/MD approach indicates that
derivative 4 also exhibits a significant degree of flexibility
(Figure 4). As previously observed for 3, ring III presents two
different puckerings characterized by phase angles around 5°
and 170° and relative populations of 30:70, respectively. The
polar interaction between NH2I and the carboxylate present in
III (see Figure 4) seems to be compatible with the presence of
relatively wide fluctuations around the I/II and III/II glycosidic
linkages.
The obtained ensembles of conformers for 2-4 that quanti-
tatively reproduce the experimental data are shown in Figure
5. These ensembles were compared to that obtained for the
natural antibiotic 1 in the free (experimentally derived from the
NMR data)16 and RNA-bound (derived from unrestrained MD
simulations of the neomycin-B/A-site complex) states.16 As
expected, analogues 2-4 are more rigid than 1 in the free state.
The RMSD for heavy atom superimposition for the ensemble
corresponding to 1 in the free state is 2.1 Å changing to 0.4 Å
for the bound ligand. The corresponding values for 3 and 4 are
1.6 Å. The conformational restriction imposed by covalently
bonding C5III to N2I in 2 is especially severe with an RMSD
value of 0.9 Å.
Interestingly, the locked aminoglycosides 2-4 closely re-
semble the bioactive conformation of the natural antibiotic. The
most representative minimum energy conformations present in
solution for 2 and 3, superimposed on the X-ray structure of
paromomycin in complex with A-site RNA, are shown in Figure
6. For 2, deviations in …/¾ values with respect to the
paromomycin bound structure are less than 11° and 21° for the
I/II and III/II linkages, respectively. The corresponding devia-(27) Altona, C.; Sundaralingham, M. J. Am. Chem. Soc. 1972, 94, 8205-8208.
Scheme 4 a
a (a) Triisopropylsilyl trifluoromethanesulfonate (TIPSOTf), 2,6-lutidine, THF, rt, 1 h, 80%; (b) Ac2O, Py, rt, 5 h, 100%; (c) HFâPy, THF, rt, 5 h, 90%;
(d) Dess-Martin periodinane, CH2Cl2, rt, 2h, 79%; (e) Ph3PdCHCO2Me, CH3CN, rt, 3h, 82%; (f) NaBH4, cat. LiCl, EtOH/THF, rt, 12 h, 89%; (g) TIPSOTf,
2,6-lutidine, THF, 0 °C, 1 h, 60%; (h) Ac2O, Py, rt, 5h, 100%; (i) HFâPy, THF, rt, 5 h, 79%; (j) p-toluenesulfonyl chloride (TsCl), Py, cat. DMAP, rt, 3
h, 79%; (k) cat. KCN, MeOH/THF 2:1, rt, 10 h, 58%; (l) H2 (1 atm), Pd/C, MeOH, trifluoroacetic acid, rt, 8 h, 88%; (m) H2O, pH 7.0, 40 °C, 10 d, 62%;
(n) H2 (1 atm), Pd/C, MeOH, trifluoroacetic acid, rt, 48 h, 60%; In 14, 15, and 17 R1) 2,6-diamino-2,6-di-N-(benzyloxycarbonyl)-2,6-dideoxy-â-L-idose.
In 10-13 and 16 R2 ) 3,4-di-O-acetyl-2,6-diamino-2,6-di-N-(benzyloxycarbonyl)-2,6-dideoxy-â-L-idose.
Conformationally Locked Aminoglycosides A R T I C L E S
J. AM. CHEM. SOC. 9 VOL. 128, NO. 1, 2006 105
tions for 3 are larger (15° and 45°). However, the global shape
of the molecule is very similar to that observed for paromomycin
in the RNA-bound state, as shown by the low RMSD values
for heavy atom superimposition (see Figure 6).
Previous studies have shown that neomycin-B in solution is
characterized by a remarkable flexibility, with different con-
formations around the three glycosidic linkages and two different
conformational populations for the unit III furanose ring (with
phase angles 20° and 160° and populations of 60-70% and
30-40%, respectively) in fast exchange.16 On the other hand,
MD simulations of neomycin-B complexed to ribosomal A-site
RNA suggest that its flexibility is severely reduced upon binding
and only one of the furanose conformations is selected by the
RNA receptor. Interestingly, in analogue 2, the unit III furanose
is locked in a very similar conformation to that present in the
A-site/paromomycin complex, with an almost identical orienta-
tion of the key polar groups, O2 and O3 (Figure 6).
In conclusion, according to our structural analysis, derivatives
2-4 satisfy the basic requirements for an optimal conforma-
tionally constrained derivative; they are all more rigid than the
natural antibiotic neomycin-B and closely resemble its bioactive,
RNA-bound conformation.
Fluorescence-Based Analysis of the Interaction between
Aminoglycosides 1-6 and the Ribosomal Decoding Site. As
a next step, the binding properties of compounds 1-4 to
ribosomal RNA were analyzed. It is known that, for natural
paromomycin, OH5III is involved in RNA recognition.5,6 Cy-
clization of neomycin-B to give 2 and 3 requires the removal
of this OH group. To isolate the effect of rigidification on the
aminoglycoside-RNA interaction, the binding properties of the
deoxyderivatives 5 and 6 were also tested. The fluorescence-
based approach, developed independently by Pilch28 and Her-
mann,29 was employed. This methodology makes use of a
modified 27-mer RNA fragment (A-site(2AP)) including the
A-site sequence and the fluorescent base analogue 2-amino-
purine (2AP) replacing A1492 (Figure 7a). It is well established
that major groove binding of aminoglycosides to the A-site
induces a significant conformational change in the RNA so
that the adenine residues at positions 1492 and 1493 are
displaced from the helical stack toward the minor groove.5-7
As the fluorescence of 2AP is modulated by hydrophobic
stacking interactions, the employed RNA fragment (shown in
Figure 7a) provides an adequate means for monitoring and
quantifying the destacking of A1492 that accompanies complex
formation.
It has been shown that paromomycin binding to the A-site(2AP)
induces a marked increase in the fluorescence intensity at 369
nm. These changes were monitored as a function of the [drug]/
[RNA] ratio in titration experiments, to derive Kd values. Some
typical binding curves are shown in Figure 7b. The affinity
constants measured for compounds 1-6 are shown in Figure
8. According to our titration experiments, natural neomycin-B
binds to the A-site with a Kd value of 0.07 íM in 100 mM
NaCl, 10 mM phosphate and pH 7.6. This result is in agreement
with previously reported values obtained by other methods under
comparable experimental conditions.30
The maximum fluorescence increases observed for the
neomycin-B derivatives (2, 3, 5, and 6) are similar to that
detected for the parent compound (1), suggesting the presence
of similar binding modes. The corresponding Kd values are
shown in Figure 8a. It can be observed that deoxy derivatives
5 and 6 present a 10-fold reduction in affinity with respect to
the natural compound 1. This result is not unexpected as OH5III
is involved in a hydrogen bond with G1491 in the paromomycin/
A-site complex. Therefore, the ¢G contribution of this hydro-
gen bond can be estimated as 1.3 kcal/mol. The observed
affinities for the macrocyclic derivatives 2 and 3 are in the same
range of those observed for the corresponding open deoxy-
analogues 5 and 6, respectively. According to these data, under
the employed experimental conditions, the ¢G contribu-
tion resulting from the conformational restriction is almost
negligible. 31,32
(28) Kaul, M.; Barbieri, C. M.; Pilch, D. S. J. Am. Chem. Soc. 2004, 126, 3447-
3453.
(29) Shandrick, S.; Zhao, Q.; Han, Q.; Ayida, B. K.; Takahashi, M.; Winters,
G. C.; Simonsen, K. B.; Vourloumis, D.; Hermann, T. Angew. Chem., Int.
Ed. 2004, 43, 3177-3182.
(30) (a) Wang, Y.; Hamasaki, K.; Rando, R. R. Biochemistry 1997, 36, 768-
779. (b) Ryu, D. H.; Litovchick, A.; Rando, R. R. Biochemistry 2002, 41,
10499-10509. (c) Fourmy, D.; Recht, M. I.; Puglisi, J. D. J. Mol. Biol.
1998, 277, 347-362.
Table 1. Experimental and Theoretical Distances (above) and
Coupling Constant Values (below) Obtained for Compounds 2, 3,
and 4 at pH 5.0a
compound 2 compound 3 compound 4
d(Å) expmt
MD-tar
(5 ns) expmt
MD-tar
(80 ns) expmt
MD-tar
(5 ns)
H1I-H4II 2.4 2.4 2.4 2.3 2.5 2.5
H1I-H5II >3.3 3.8 3.3 3.2
H1I-H1III >3.3 4.5 3.9 4.0
H1I-H2III >3.3 3.7 3.4 3.2
H1I-H3III >3.3 3.3
H1I-H5III R 2.4 2.3 >3.3 5.1
H1I-H5III S >3.3 3.3
H1I-H6III R/S >3.3/>3.3 3.3/4.6
H1I-H7III R/S >3.3/>3.3 3.3/3.6
H2I-H5III R <2.4 2.4
H2I-H7III R 2.6 2.6
H3I-H7III R/S >3.3/>3.3 3.5/3.3
H1III-H5II 2.6 2.6 2.2 2.3 2.5 2.5
H1III-H4II >3.5 4.5 >3.3 4.4
H1III-H6II 3.5 3.6 >3.3 3.7 3.6 3.3
H1III-H4III 3.6 3.7 3.1 3.0 3.5 3.3
H2III-H7III R/S >3.3/>3.3 3.3/4.9
H2III-H6II >3.3 4.2 3.2 3.3
H2III-H6III R/S >3.3/>3.3 4.9/3.4
H2III-H5III R <2.4 2.2
H3III-H7III R/S >3.3/>3.3 3.3/4.6
H3III-H6III R/S >3.3/>3.3 4.3/3.2
H4III-H6III R/S >3.3/>3.3 3.2/3.8
H1IV-H2III >4 4
H1IV-H3III 2.5 2.6 2.5 2.3 2.4 2.5
H1IV-H4III 3.5 3.5 >3.3 4.0 3.8 3.9
J (Hz) expmt
MD-tar
(5 ns) expmt
MD-tar
(80 ns) expmt
MD-tar
(5 ns)
H1III-H2III 3.9 4.5 3.5 4.1 3.9 4.0
H2III-H3III 4.9 4.2 4.0 4.1
H3III-H4III <1.0 1.1 3.5 4.5 4.4 4.3
H4III-H5III R 11.6 11.0 <3.5 4.1
H4III-H5III S 4.0 4.7 9.5 8.8
H7III R-H6III R 3.0 3.4
H7III R-H6III S 8.5 7.9
H7III S-H6III R 7.0 7.2
a Molecular dynamic simulations with time-averaged restraints (MD-
tar) for compounds 2 and 4 were carried out using explicit solvent,
counterions, periodic boundary conditions (PBC), and Ewald sums for the
treatment of electrostatic interactions. For compound 3, in vacuo 80 ns MD-
tar trajectories were collected (see the Materials and Methods). The
stereochemistry of the protons involved in the distance constraints is
indicated when appropriate.
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Conformational freedom has been shown to play a key role
in the recognition of ligands by receptors.33 Several attempts
have been made to exploit the decrease of conformational
entropy of a particular ligand by either locking or biasing
conformations toward the bioactive one. In some cases, the
constrained derivatives presented significantly larger affinities
for the receptor than the natural ligand.34 In contrast, reported
results for carbohydrate-protein interactions range from modest
¢G benefits (<0.5 kcal/mol)35 to small penalties35,36 (<0.3 kcal/
mol). In these cases, the small effect of the conformational
constraint on the global ¢G has been attributed to an entropy-
enthalpy compensation phenomenona.36 Our results indicate that
despite the different chemical nature of both the ligand and the
receptor, aminoglycoside-RNA interactions exhibit a similar
behavior to those previously observed in the recognition of
neutral carbohydrates by proteins. Especially striking is the lack
(31) While this manuscript was in preparation, Tor and co-workers reported
the interaction of both the locked derivative 2 and the corresponding
paromomycin analogue with the same labeled A-site RNA fragment.
Although the buffer conditions employed for the fluorescence measurements
differ from ours, the reported decrease in affinity for the locked derivatives
is 22-14-fold with respect to the parent aminoglycosides, in agreement
with our results; Blount, K. F.; Zhao, F.; Hermann, T.; Tor, Y. J. Am.
Chem. Soc. 2005, 127 (27), 9818-9829.
(32) The 3D structure of derivative 2 in complex with the A-site, reported by
Hermann and col while this manuscript was under revision, shows that
rings III and IV present a slightly different orientation in the RNA major
groove from that observed for natural Neomycin-B. As a result, the number
of ligand-RNA contacts established by these two units is reduced. Zhao,
F.; Zhao, Q.; Blount, K. F.; Han, Q.; Tor, Y.; Hermann, T. Angew. Chem.,
Int. Ed. 2005, 44, 5329-5334.
(33) (a) Williams, D. H.; Searle, M. S.; Mackay, J. P.; Gerhard, U.; Maplestone,
R. A. Proc. Natl. Acad. Sci. U.S.A.. 1993, 90, 1172-1178. (b) Calderone,
C. T.; Williams, D. H. J. Am. Chem. Soc. 2001, 123, 6262-6267.
(34) (a) Choi, Y.; Moon, H. R.; Yoshimura, Y.; Marquez, V. E. Nucleoside
Nucleotide Nucleic Acids 2003, 22, 547-557. (b) Kim, H. S.; Ohno, M.;
Xu, B.; Kim, H. O.; Choi, Y.; Ji, X. D.; Maddileti, S.; Marquez, V. E.;
Harden, T. K.; Jacobson, K. A. J. Med. Chem. 2003, 46, 4974-4987.
(35) Navarre, N.; Amiot, N.; van Oijen, A. H.; Imberty, A.; Poveda, A.; Jime´nez-
Barbero, J.; Nutley, M. A.; Boons, G. J. Chem. Eur. J. 1999, 5, 2281-
2294.
(36) Bundle, D. R.; Alibe´s, R.; Nilar, S.; Otter, A.; Warwas, M.; Zhang, P. J.
Am. Chem. Soc. 1998, 120, 5317-5318.
Figure 1. (a) Selective 1D NOE experiments with the 1D-DPFGSE NOE pulse sequence, corresponding to the inversion of H5III and H1I in compound 2.
Key NOEs probing the spatial proximity of units I and III are highlighted in the upper part of the figure. The numbering employed for the different sugar
units is also indicated. (b) MD-tar …/¾ distributions obtained for the I/II (upper panel) and III/II (lower panel) glycosidic linkages. The values corresponding
to the paromomycin-RNA bound form are indicated with a yellow dot.
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of effect that preorganization of the unit III furanose has on the
binding strength. Close inspection of molecular models shows
that the global shape of the antibiotic is extremely dependent
on the precise puckering of this ring. In fact, the specific drug-
RNA contacts observed in the paromomycin-RNA complex,5,6
involving units III and IV and presumably required for tight
binding, are only feasible when the furanose adopts a puckering
in the “South” region of the pseudorotational path, which is
the minor one in the free state. Nevertheless, the original NMR
studies by Puglisi and co-workers7 showed that, for paromo-
mycin, these rings are dynamic in the ribosome-bound state,
and therefore the contacts observed in the crystal structure of
the complex might be transient. In addition, the Westhof and
Hanessian groups have recently described, for a paromomycin
derivative, a new binding mode to the A-site, for which the
ribose ring (unit III) is recognized by the RNA receptor in a
C2-endo conformation.37
Finally, for compound 4, the maximum increase in fluores-
cence observed upon complex formation is less than half the
value observed for neomycin-B, suggesting a smaller structural
change in the receptor upon complex formation. It is known
that, in the paromomycin-A-site complex, OH5III is located in
a strongly electronegative region of the RNA binding pocket.
Probably, the substitution of this OH group by a negatively
charged carboxylate precludes a deep penetration of the ligand
in the major groove. However, despite this modification, the
observed affinity for 4 is in the micromolar range.
Effect of the Conformational Constraint on the Antibiotic
Activity. The biological activity of the locked neomycin-B
derivatives 2-4 was tested against E. coli (see Table 2). For
derivative 2, a more extensive testing was performed employing
both Gram+ and Gram- bacteria. Despite the observed decrease
in activity with respect to the natural compound 1 (3-20-fold
depending on the bacteria and the compound), derivatives 2 and
3 are still significantly active (with MIC values in the 2.5-20
íg/mL range). In contrast, derivative 4 showed a poor antibiotic
activity. This suggests that 4 is adversely affected by other
factors such as a different binding mode (as suggested by
fluorescence experiments above), different kinetics for crossing
the bacterial membrane, digestion or modification by bacterial
enzymes, etc. With respect to 2 and 3, the obtained results show
a good correlation with the binding affinities previously
measured for ribosomal RNA and indicate that these locked
derivatives might potentially be employed as antibiotics.
Therefore, the inactivation of these analogues by aminoglycoside
modifying enzymes was tested.
Effect of the Conformational Constraint on Aminoglyco-
side Inactivation by Bacterial Defense Proteins. To analyze
the effect that conformational restriction has on the antibiotic
enzymatic inactivation, three different enzymes were chosen as
model systems: Staphylococcus aureus ANT(4′), Myco-
bacterium tuberculosis AAC(2′), and Enterococcus faecalis
APH(3′). These proteins are representative of the three main
families of enzymes that modify aminoglycosides: adenyltrans-
ferases, acyltransferases, and phosphotransferases. In addition,
there is high-resolution X-ray structural information available
(37) Francois, B.; Szychowski, J.; Adhikari, S. S.; Pachamuthu, K.; Swayze, E.
E.; Griffey, R. H.; Migawa, M. T.; Westhof, E.; Hanessian, S. Angew.
Chem., Int. Ed. 2004, 43, 6735-6738.
Figure 2. (a) Selective 1D NOE experiments with the 1D-DPFGSE NOE pulse sequence, corresponding to the inversion of the anomeric protons in compound
3. (b) Upper panel: Schematic representation of some of the experimental information employed in the structural analysis of 3. The upper left panel shows
the observed NOEs as red arrows and those not observed as blue arrows. The upper right panel shows the structurally relevant experimental J couplings
measured for 3. The ring IV is omitted for simplicity. Lower panel: some representative NOE buildup curves. NOEs corresponding to known fixed distances,
employed as references, are labeled in gray. NOEs corresponding to unknown distances are labeled in red.
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for the three enzymes in complex with several antibiotics.
Analysis of these data permits the deduction of either minor
(as in APH(3′)) or major (as in ANT(4′) or AAC(2′)) confor-
mational differences, for the aminoglycoside, in the protein-
bound state with respect to the RNA-bound state (see Scheme
1).15,17,19
Staphylococcus aureus ANT(4′) catalyzes the transfer of one
adenyl group from ATP to position O-4 (see Scheme 1) of ring
I. This transfer leads to a sharp decrease in the drug affinity for
its target RNA. The 3D structure of ANT(4′) complexed to
kanamycin has been determined by using X-ray.15 In addition,
the structures of related analogues, such as gentamycin, tobra-
mycin, and paromomycin bound to the target ribosomal RNA
have also been determined recently.5,6 Interestingly, the oligo-
saccharide conformation recognized by the RNA and by the
enzyme is remarkably different, as previously mentioned (see
Scheme 1). If it is assumed that some degree of conformational
distortion at the I /II fragment is in fact required for enzymatic
activity, the conformational restriction introduced in derivatives
2 and 3 might provide a certain degree of protection against
the enzymatic inactivation of the antibiotic.
To test this hypothesis, enzymatic reactions were monitored
in NMR tubes. ATP (100 íM-3 mM) and the aminoglycosides
(100 íM-1.5 mM) were dissolved in phosphate buffer (10 mM
phosphate, 2.5-5.0 mM MgCl2, pH 7.0). After addition of the
enzyme (0.2-1.0 íM), the evolution of the reaction mixture at
310 K was monitored by 1D NMR, and the final products were
characterized by 2D NMR and MALDI-TOF MS. As shown in
Figure 9, at 100 íM neomycin-B, 100 íM ATP, 2.5 mM MgCl2,
and 0.2 íM ANT(4′), the adenylation reaction is completed
within 22 min. NMR analysis permitted us to confirm that
ANT(4′) selectively modifies OH4I. In fact, if only 1 equiv of
ATP is employed, this is the only product detected. Interestingly,
if 2 ATP equiv are used, nonselective secondary adenylations
are detected but at much longer reaction times. For example, at
3 mM ATP, 1.5 mM neomycin-B, 5 mM MgCl2 (pH 7.0, 310
K), and 1 íM ANT(4′), the primary adenylation is completed
in 2 min. In contrast, the enzyme requires more than 12 h to
consume the second ATP equivalent, once the primary adenyl-
ation is completed. The presence of diadenylated neomycin-B
derivatives were confirmed by MALDI-TOF.
For the rigid analogue 2, at 100 íM aminoglycoside, 100
íM ATP, 2.5 mM MgCl2, and 0.2 íM ANT(4′), no reaction
was detected even 24 h after enzyme addition (see Figure 9).
At larger ANT(4′) concentrations (up to 1 íM ANT(4′)), slow,
nonselective adenylation processes (similar to those described
above for 1) were observed. In contrast, the related deoxy
derivative 5 reacted smoothly to give the monoadenylated
compound within a few minutes, which demonstrates that the
behavior exhibited by 2 has its origin in the extra rigidity of
the antibiotic and that it is not related to the absence of OH5III.
Therefore, the simple modification leading to conformationally
Figure 3. (a) MD-tar …/¾ distributions obtained for the I/II (upper panel) and III/II (lower panel) glycosidic linkages in compound 3. Minimum energy
geometries are indicated with a cyan dot. The …/¾ values observed for the ligand in the paromomycin-RNA complex are indicated with a yellow dot. (b)
Representation of the major conformational populations detected in solution for 3. Unit IV is omitted for simplicity.
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restricted 2 provides an effective protection against aminogly-
coside inactivation by S. aureus ANT(4′).
Surprisingly, the locked analogue 3 exhibited a similar
behavior to that observed for the natural antibiotic, neomycin-
B. Indeed, the specific activities of ANT(4′) for aminoglycosides
1 and 3 are almost identical (see Figure 9). According to these
data, it seems that ANT(4′) is able to recognize and inactivate
aminoglycoside conformations different from the anti-¾ ge-
ometry observed in the enzyme-kanamycin complex15 by X-ray
methods. In fact, this conformation is not accessible for
derivative 3. In any case, these results prove that some degree
of conformational flexibility in the ligand is critical for
enzymatic activity. For ANT(4′) a strong conformational restric-
tion (as present in 2) prevents the antibiotic enzymatic adenyl-
ation, although the limited flexibility present in 3 restores the
enzymatic activity.
In vivo activities of neomycin-B (1) and mimic 2 were tested
employing the bacteria E. coli DH5R (pBBR1MCS-2), which
expresses the resistance enzyme ANT(4′). As expected, the MIC
value for the natural antibiotic is significantly increased (from
3 to 60 íg/mL). In contrast, the cyclic derivative 2 maintains
the same activity observed for the nonresistant bacteria (20 íg/
mL). In conclusion, this simple modification leading to the
conformationally restricted 2 provides an effective protection
Figure 4. (a) Upper panel: Schematic representation of some of the observed NOEs employed in the structural analysis of 4. The salt bridge interaction
between units III and I is highlighted with a dotted box. Lower panel: Representative NOE build-up curves. (b) MD-tar …/¾ distributions obtained for the
I/II (upper) and III/II (lower) glycosidic linkages. Minimum energy geometries are indicated with a cyan dot. The …/¾ values corresponding to the
paromomycin-RNA bound form are indicated with a yellow dot.
Figure 5. MD-tar ensembles of conformers for 2-4. The experimental ensemble corresponding to 1 in the free state (left) and that obtained from MD
simulations of the neomycin-RNA complex16 (right) are shown for comparison. RMSDs (Å) for heavy atom superimposition are given below. The numbering
employed for the different sugar units is shown on the right.
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against aminoglycoside inactivation by S. aureus ANT(4′), both
in vivo and in vitro, while maintaining a significant antibiotic
activity.
Mycobacterium tuberculosis AAC(2′) catalyzes the transfer
of one acetyl group from Acetyl CoA to position N-2 (see
Scheme 1) of the ring I. The 3D structure of AAC(2′) complexed
to ribostamycin has been recently determined by X-ray.17 As
previously mentioned, the oligosaccharide conformations bound
by the RNA and by the enzyme are remarkably different (see
Scheme 1). Interestingly, the recognition of a high energy
conformation of the antibiotic seems essential for the enzymatic
activity. Thus, by forcing an anti-¾ geometry around the III/II
linkage, the protein increases the accessibility of the reacting
NH2I group which, otherwise, would be hydrogen-bonded to
the nonvicinal unit III in the low energy syn-¾ minimum.
According to the conformational analysis described above, for
cyclic derivatives 2 and 3, this conformational change is no
longer possible. Therefore, the geometrical restriction introduced
in these derivatives is expected to fully protect the antibiotics
from the enzymatic acetylation. To test this hypothesis, enzy-
matic reactions were performed in NMR tubes employing
similar conditions as those previously described for ANT(4′)
(see Materials and Methods). As shown in Figure 10, at 100
íM neomycin-B, 100 íM AcCoA, 2.5 mM MgCl2, and 0.2 íM
AAC(2′), the acetylation reaction is completed within 1 h. A
similar behavior was observed for the deoxy derivatives 5 and
6. In contrast, no reaction was observed for the locked
aminoglycosides 2 and 3, even after 24 h and higher enzyme
concentrations (0.2-20 íM). Therefore, the conformational
constraint introduced in 2 and 3 provides complete protection
against aminoglycoside modification by AAC(2′).
The in vivo activities of neomycin-B (1) and mimic 3 were
tested employing the bacteria E. coli BL21(DE3)(pET23a-
AAC(2′)), which expresses the resistance enzyme AAC(2′). The
MIC values measured for 1 and 3 were 2 and 2.5 íg/mL,
respectively. As expected, 3 is not affected by the expression
of AAC(2′), and this locked aminoglycoside exhibits a good
antibiotic activity. However, under the employed experimental
conditions, the AAC(2′) enzymatic activity seems to have a low
influence on the antibiotic properties of the natural compound
1. Although merely speculative, acetylation at position 2 of ring
I might have a small influence on the stability of the drug/A-
site complex. In fact, according to the structural information
available,5-7 the amino group located at this position of the
antibiotic is not involved in any key contact with the RNA target,
and therefore acetylated 1 might retain a significant activity.
Finally, the effect of neomycin-B flexibility on its enzymatic
inactivation by Enterococcus faecalis APH(3′) was tested. This
enzyme catalyzes the transfer of a phosphate group from ATP
to position 4 (see Scheme 1) of ring I. In this case, the X-ray
structure of the enzyme in complex with neomycin-B shows
that the antibiotic structure recognized by the enzyme and the
target RNA are remarkably similar (see Scheme 1). In fact, they
mainly differ in the conformation adopted by the furanose ring
of III (C3-endo and close to C2-endo for the RNA- and enzyme-
bound conformations, respectively).
As shown in Figure 11, at 100 íM neomycin-B, 100 íM
ATP, 2.5 mM MgCl2, and 0.2 íM APH(3′), a 50% antibiotic
transformation is achieved in 17 min, and the reaction is almost
complete in 40 min. Under identical conditions, the enzyme
needs 35 min to modify 50% of analogue 3. For the more rigid
derivative 2, the reaction is even slower (around 100 min for a
50% transformation). In conclusion, although the extra rigidity
Figure 6. Structures representative of the main conformational families
present in solution for neomycin-B derivatives 2 (left) and 3 (right)
superimposed on the X-ray structure of paromomycin in the complex with
ribosomal RNA, according to X-ray data. The maximum …/¾ deviations
(for each glycosidic linkage) and RMSD (Å) values for heavy atom
superimpositions are shown. Unit IV is omitted for simplicity.
Figure 7. (a) Schematic representation of the modified RNA fragment employed in our binding studies and the structural change induced by aminoglycoside
binding. (b) Some representative binding curves obtained for derivatives 1 (black), 2 (red) and 3 (cyan) under identical conditions.
Table 2. Experimental MIC Values (íg/mL) Measured for
Neomycin-B and Its Conformationally Constrained Analogues 2-4
MICs (íg/mL)
1 2 3 4
E. coli (DH5R) 3 20 9 >100
E. coli (BL21) 0.50 10 2.5
S. epidermis 2 10
Bacillus cereus 1 5
Alcaligenes faecalis 1 20
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of the locked derivatives provides a certain protection against
modification by APH(3′), in this case, it is insufficient to prevent
the enzymatic inactivation of the drugs. This result is not totally
unexpected, given the close similarity of the aminoglycoside
structures in the binding pockets of both receptors (the A-site
RNA and the enzyme).6,7,19
The in vivo activities of neomycin-B (1) and mimic 2 were
tested employing the bacteria E. coli DH5R(pACYC177), which
expresses the resistance enzyme APH(3′). The MIC values for
the natural antibiotic and cyclic derivatives 2 and 3 were in all
cases >150 íg/mL. Therefore, in this case, although the extra
rigidity present in compound 2 provides a certain in vitro
protection against the antibiotic enzymatic inactivation, this is
clearly insufficient to warrant a good biological activity.
Conclusions
We have shown that the conformational differences exhibited
by aminoglycosides within the binding pockets of the ribosome
and of those enzymes involved in bacterial resistance can, in
certain favorable cases, be exploited for designing new antibiotic
derivatives not susceptible to enzymatic inactivation. Thus, the
neomycin-B locked derivatives 2 and 3 have been specifically
designed to mimic the bioactive RNA-bound structure of the
drug. In fact, both antibiotics maintain a reasonable affinity for
the target A-site RNA and exhibit significant biological activi-
ties. For compound 2, the conformational constraint provides
full protection against the aminoglycoside modification by
Staphylococcus aureus ANT(4′) and Mycobacterium tubercu-
losis AAC(2′) and partially protects against modification by
Enterococcus faecalis APH(3′). In fact, 2 presents an improved
biological activity with respect to neomycin-B in bacteria
expressing Staphylococcus aureus ANT(4′). In addition, deriva-
tive 3 is not susceptible to modification by Mycobacterium
tuberculosis AAC(2′). However, for derivatives 2 and 3, the
price paid in terms of RNA binding affinity is not negligible
(around 1.6 kcal/mol in ¢G). Clearly, more structure activity
studies are needed in the future to address this problem.
Interestingly, our RNA binding studies show that for these
compounds the observed decrease in affinity has its origin,
mainly, in the loss of the OH at position 5 of ring III. In contrast,
the conformational restriction does not seem to be critical.
According to X-ray studies OH5III is involved in a hydrogen
bond with G1491 in the neomycin-B/ribosome complex. Our
results indicate that this particular interaction plays a significant
role in the stabilization of the complex. Thus by participating
in a direct ligand-RNA interaction the OH5III might help to
maintain an appropriate orientation of units III and IV within
the RNA binding pocket.32 Therefore, efforts should be made
in future to optimize the ligand-RNA contacts established by
rings III and IV while maintaining the conformational restriction.
In our opinion, this example represents a test case for the
validity of a structure-based approach for the design and
preparation of ligands that specifically interact with a given
receptor and that, in this particular case, might potentially be
used as antibiotics. Finally, we would like to stress that the utility
of conformational restriction to prevent the enzymatic inactiva-
tion of a particular drug while preserving its biological activity
might not be restricted to aminoglycosides and could find further
applications within medicinal chemistry.
Figure 8. (a) Kd values obtanied for aminoglycosides 1-6. (b) Schematic
representation of the ¢G values measured for the binding of aminoglycosides
1, 2, 3, 5 and 6 to the A-site.
Figure 9. Time evolution (at pH 7.0 and 310 K) of neomycin-B (1, left), derivative 2 (middle), and derivative 3 (right) at 100 íM concentration in the
presence of ATP (100 íM), phosphate (10 mM), and MgCl2 (2.5 mM) after addition of 0.2 íM ANT(4′) followed by 1-D NMR. For derivative 2, no reaction
was detected. 1-Ad and 3-Ad stand for the adenylated derivatives 1 and 3, respectively. The aminoglycoside position modified by the enzyme is shown
schematically in the inset.
A R T I C L E S Bastida et al.
112 J. AM. CHEM. SOC. 9 VOL. 128, NO. 1, 2006
Materials and Methods
Synthesis of the Aminoglycoside Derivatives. Compound 8.
Compound 7 (500 mg, 0.34 mmol) was dissolved in pyridine (10 mL),
and 2,4,6-triisopropylbenzene sulfonyl chloride (3.2 g, 10.6 mmol) was
added under argon at rt. After stirring for 72 h, the mixture was diluted
with EtOAc (300 mL) and H2O (100 mL) and then neutralized with 1
N HCl. The aqueous phase was extracted with EtOAc (2  100 mL),
and the combined organic layers were washed with brine (50 mL), dried
over Na2SO4, and evaporated at reduced pressure; the crude was purified
by column chromatography on silica gel (CH2Cl2/MeOH, 20:1) to give
8 (250 mg, 44%). Rf ) 0.5 (CH2Cl2/MeOH 10:1). 1H NMR (500.13
MHz, CD3OD ): ä 7.4-7.2 (m, 30H, CH2Ph), 5.43 (broad s, anomeric
proton), 5.24 (broad s, anomeric proton), 5.08 (broad s, anomeric
proton), 5.2-5.0 (m, 12H, CH2Ph), 2.91 (m, 3H, CH(CH3)2), 1.21 (18H,
CH(CH3)2). 13C NMR (75.47 MHz, CD3OD): 130-129 (CH2Ph), 111.0
(anomeric carbon), 99.8 (anomeric carbon), 99.0 (anomeric carbon),
69-68, (CH2Ph), 35.5 (CH(CH3)2), 35.4 (C2II), 25.4 (CH(CH3)2), 81.8,
81.1, 71.8, 71.2, 69.3, 57.7, 54.2, 52.8, 52.6, 43.3, 42.8. MALDI-TOF
m/z 1708.3 [M + Na+].
Compound 9. Palladium on charcoal (1:5 catalyst/substrate by
weight) was added to a solution of 8 (50 mg, 0.030 mmol) and
trifluoroacetic acid (20 íL, 0.26 mmol) in MeOH (3 mL). After the
Figure 10. Time evolution (at pH 7.0 and 310 K) of neomycin-B (left), derivative 2 (middle), and derivative 3 (right) at 100 íM concentration in the
presence of AcCoA (100 íM) and phosphate (10 mM) after addition of 0.2 íM AAC(2′), followed by 1-D NMR. For derivatives 2 and 3, no reaction was
detected even after 24 h, independently of the concentration of the enzyme employed. 1-Ac stands for acetylated neomycin-B. The aminoglycoside position
modified by the enzyme is shown schematically in the inset. The X-ray structure of ribostamycin in complex with AAC(2′) is also represented.
Figure 11. Time evolution (at pH 7.0 and 310 K) of neomycin-B (left), derivative 2 (middle), and derivative 3 (right) at 100 íM concentration in the
presence of ATP (100 íM), phosphate (10 mM), and MgCl2 (2.5 mM) after addition of 0.2 íM APH(3′) followed by NMR. 1-P, 2-P, and 3-P stand for the
modified antibiotics 1, 2 and 3, respectively. The aminoglycoside position modified by the enzyme is shown schematically in the inset.
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suspension was stirred under H2 (1 atm), at rt for 8 h, the catalyst was
removed by filtration, and the solvent was evaporated to give 9 (24
mg, 90%), which was used in the next step without further purification.
Rf ) 0.21 (NH4OH/CHCl3/n-BuOH/EtOH 3:1:2:2.5) 1H NMR (500.13
MHz, D2O ): ä 5.55 (broad s, 1H, H1I), 5.25 (broad s, 1H, H1III), 5.01
(broad s, 1H, H1IV), 1.90 (m, 1H, H2II equatorial), 1.15 (m, 1H, H2II
axial). MALDI-TOF m/z 903.7 [M + Na+].
Compound 2. A diluted solution of 9 (50 mg, 0.056 mmol) in H2O
(100 mL, pH 7.0) was stirred at 60 °C for 5 days. The solvent was
removed at reduced pressure, and the crude was purified by ion
exchange column chromatography (0.5 cm  7 cm) with Amberlite
CG-50 (0-7.5% NH4OH) to give, after lyophilization, compound 2
(18 mg, 56%). Rf ) 0.16 (NH4OH/CHCl3/n-BuOH/EtOH 3:1:2:2.5).
1H NMR (500.13 MHz, D2O ): ä 5.75 (d, J ) 3.9 Hz, 1H, H1III), 5.20
(d, J ) 3.5 Hz, 1H, H1I), 5.03 (broad s, 1H, H1IV), 2.72 (1H, H5III),
2.55 (1H, H2I ), 1.95 (m, 1H, H2II equatorial), 1.16 (m, 1H, H2II axial).
13C NMR (75.47 MHz, D2O): ä 100.3 (C1IV), 109.5 (C1III), 98.2 (C1I),
60.7 (C2 I), 48.4 (C5III). MALDI-TOF m/z 619.1 [M + Na+].
Compound 10. To a solution of compound 7 (1.0 g, 0.7 mmol) in
dry THF (7 mL) at 0 °C under argon was added 2,6-lutidine (0.24 mL,
2.1 mmol) and TIPSOTf (0.28 mL, 1.05 mmol). The mixture was
allowed to warm to rt and stirred for 1 h. The solvent was evaporated,
and the crude was purified by flash chromatography (CH2Cl2/MeOH,
15:1) to give the silyl ether derivative (0.88 g, 80%). Rf ) 0.4 (CH2Cl2/
MeOH 10:1). To a solution of this derivative (1.0 g, 0.63 mmol) in
pyridine (15 mL) was added at rt Ac2O (7 mL). After the mixture was
stirred for 5 h at rt, the solvent was removed at reduced pressure, and
the crude was purified by column chromatography on silica gel (EtOAc/
hexane, 1:1) to give 10 (1.02 g, 100%). Rf ) 0.6 (EtOAc/hexane 2:1).
1H NMR (500.13 MHz, CD3OD): ä 7.4-7.2 (m, 30H, CH2Ph), 5.2-
5.0 (12H, CH2Ph), 2.1-1.8 (18H, CH3CO2), 1.97 (m, 1H, H2II
equatorial), 1.36 (m, 1H, H2II axial), 1.32 (m, 3H, SiCH(CH3)2), 1.10
(18H, SiCH(CH3)2). 13C NMR (75.47 MHz, CD3OD ): 130-129
(CH2Ph), 69-68, (CH2Ph), 35.4 (C2II), 21-20 (CH3CO2), 18.5
(SiCH(CH3)2). MALDI-TOF m/z 1850.2 [M + Na+].
Compound 11. To a solution of the silyl ether 10 (0.5 g, 0.28 mmol)
in dry THF (5 mL), in a polyethylene vessel at 0 °C, was added HF/
pyridine (0.3 mL). After stirring at rt for 5 h, the mixture was diluted
with Et2O and neutralized with aqueous saturated NaHCO3. The
combined organic layer was dried, evaporated, and purified by flash
chromatography (EtOAc/hexane, 1:1) to give alcohol 11 (0.42 g, 90%).
Rf ) 0.3 (AcOEt/hexane 2:1). 1H NMR (500.13 MHz, CD3OD): ä
7.4-7.2 (m, 30H, CH2Ph), 5.81 (broad s, anomeric proton), 5.72 (broad
s, anomeric proton), 5.18 (broad s, anomeric proton), 5.2-4.9 (m, 12H,
CH2Ph), 2.2-1.9 (18H, CH3CO2) 1.95 (m, 1H, H2II equatorial), 1,64
(m, 1H, H2II axial). 13C NMR (75.47 MHz, CD3OD ): 130-129
(CH2Ph), 110.5 (anomeric carbon), 98.2 (anomeric carbon), 68-67,
(CH2Ph), 34.4 (C2II), 21-20 (CH3CO2), 84.1, 83.4, 76.1, 74.1, 72.4,
69.8, 62.4, 54.9, 51.1, 42.1. MALDI-TOF m/z 1694.6 [M + Na+].
Compound 12. Dess-Martin periodinane (95 mg, 0.26 mmol) was
added to a solution of alcohol 11 (250 mg, 0.15 mmol) in CH2Cl2 (5
mL). After the mixture was stirred for 2 h at rt, Et2O was added (20
mL), and the mixture was poured into saturated aqueous NaHCO3
solution (25 mL) and Na2S2O5 (100 mg). The organic layer was washed
with saturated aqueous NaHCO3 (25 mL) and brine (25 mL) and dried,
and the solvent evaporated at reduced presure to give, after purification
by flash chromatography (EtOAc/hexane, 2:1), aldehyde 12 (199 mg,
79%). Rf ) 0.3 (AcOEt/hexane 2:1). 1H NMR (500.13 MHz, CDCl3):
ä 9.4 (broad s, 1H, CHO), 7.4-7.2 (m, 30H, CH2Ph), 5.2-4.9 (12H,
CH2Ph), 2.1-1.9 (18H, CH3CO2), 1.92 (m, 1H, H2II equatorial), 1.41
(m, 1H, H2II axial). 13C NMR (75.47 MHz, CDCl3 ): 130-129
(CH2Ph), 68-67, (CH2Ph), 34.6 (C2II), 21-20 (CH3CO2). MALDI-
TOF m/z 1691.58 [M + Na+].
Compound 13. To a solution of 12 (250 mg, 0.15 mmol) in dry
acetonitrile (6 mL) was added (methoxycarbonylmethylen)triphenyl-
phosphorane (66 mg, 0.19 mmol). After stirring at rt for 3 h, the solvent
was removed at reduced pressure, and the crude was purified by column
chromatography on silica gel (EtOAc/hexane, 1:1) to give compound
13 (215 mg, 82%). Rf ) 0.3 (AcOEt/hexane 2:1). 1H NMR (500.13
MHz, CDCl3): ä 7.4-7.2 (m, 30H, CH2Ph), 7.16 (broad m, 1H), 6.33
(broad s, 1H), 5.2-4.9 (12H, CH2Ph), 3.90 (s, 3H, CO2CH3), 2.1-1.8
(18H, CH3CO2), 1.98 (m, 1H, H2II equatorial), 1,40 (m, 1H, H2II axial).
13C NMR (75.47 MHz, CDCl3): 130-129 (CH2Ph), 68-67 (CH2Ph),
34.6 (C2II), 21-20 (CH3CO2). MALDI-TOF m/z 1748.7 [M + Na+].
Compound 14. To a solution of compound 13 (200 mg, 0.12 mmol)
in THF/EtOH (1:2, 10 mL) at rt was added NaBH4 (54 mg, 1.46 mmol)
and LiCl (6 mg, 0.15 mmol). After the mixture was stirred at rt for 12
h, EtOAc (25 mL) was added, and the mixture was washed with
aqueous saturated NaHCO3 and brine. The organic phase was dried
over Na2SO4, the solvent was removed at reduced pressure, and the
crude was purified by flash chromatography (CH2Cl2/MeOH, 20:1) to
give 14 (155 mg, 89%). Rf ) 0.4 (CH2Cl2/MeOH 10:1). 1H NMR
(500.13 MHz, CD3OD): ä 7.4-7.2 (m, 30H, CH2Ph), 5.16 (broad s,
1H, H1I), 5.04 (broad s, 1H, H1III), 5.2-5.0 (12H, CH2Ph), 4.78 (broad
s, 1H, H1IV), 1.99 (m, 1H, H2II equatorial), 1.62-1.60 (m, 4H, -CH2-
CH2-CH2-OH), 1.39 (m, 1H, H2II axial). 13C NMR (75.47 MHz, CD3-
OD): 130-129 (CH2Ph), 111.3 (C1III), 101.2 (C1I), 100.9 (C1IV), 69-
68, (CH2Ph), 35.1 (C2II), 30.6 (-CH2-CH2-CH2-OH), 29.5 (-CH2-
CH2-CH2-OH), 86.8, 82.8, 76.4, 74.9, 73.6, 73.4, 72.9, 71.6, 69.4,
63.0, 57.7, 54.2, 52.6, 43.1, 42.5. MALDI-TOF m/z 1469.7 [M + Na+].
Compound 15. Treatment of compound 14 (150 mg, 0.10 mmol)
at 0 °C following the same procedure described for the preparation of
compound 10 gave the silyl ether 15 (97 mg, 60%). Rf ) 0.4 (CH2Cl2/
MeOH 10:1). 1H NMR (500.13 MHz, CD3OD): ä 7.4-7.2 (m, 30H,
CH2Ph), 5.26 (broad s, 1H, H1I), 5.07 (broad s, 1H, H1III), 5.2-5.0
(12H, CH2Ph), 4.85 (broad s, 1H, H1IV), 1.96 (m, 1H, H2II equatorial),
1.66-1.63 (m, 4H, -CH2-CH2-CH2-OTIPS), 1,38 (m, 1H, H2II
axial), 1.04 (18H, CH(CH3)2). 13C NMR (75.47 MHz, CD3OD): 130-
129 (CH2Ph), 111.0 (C1III), 100.7 (C1IV), 100.5 (C1I), 69-68, (CH2Ph),
35.1 (C2II), 31.1 (-CH2-CH2-CH2-OTIPS), 26.7(-CH2-CH2-
CH2-OTIPS), 18.31 (CH(CH3)2), 86.7, 82.7, 82.2, 75.8, 74.7, 73.5,
73.1, 72.0, 69.3, 64.8, 57.9, 54.3, 53.3, 52.5, 43.4, 42.5. MALDI-TOF
m/z 1626.2 [M + Na+].
Compound 16. Acetylation of 15 (97 mg, 0.060 mmol) employing
the same methodology described for 10 gave the fully acetylated
derivative in quantitative yield. Rf ) 0.3 (CH2Cl2/MeOH 20:1). From
this compound (111 mg, 0.060 mmol), derivative 16 (81 mg, 0.048
mmol) was obtained following a procedure identical to that described
for 11; yield: 79%. Rf ) 0.25 (CH2Cl2/MeOH 20:1). 1H NMR (500.13
MHz, CD3OD): ä 7.4-7.2 (m, 30H, CH2Ph), 5.1-4.9 (12H, CH2Ph),
2.1-1.9 (18H, CH3CO2), 1.94 (m, 1H, H2II equatorial), 1.63 (m, 1H,
H2II axial). 13C NMR (75.47 MHz, CD3OD): 130-129 (CH2Ph), 68-
67, (CH2Ph), 34.5 (C2II), 21-20 (CH3CO2). MALDI-TOF m/z 1721.8
[M + Na+].
Compound 17. To a solution of compound 16 (81 mg, 0.048 mmol)
in pyridine (2 mL) was added DMAP (1 mg, 0.008 mmol) and
p-toluenesulfonyl chloride (14 mg, 0.073 mmol). After stirring the
mixture, at room temperature under argon for 3 h, the solvent was
evaporated and the crude was purified by flash chromatography (EtOAc/
hexane, 1:1) to give the primary sulfonate (70 mg, 79%). Rf ) 0.4
(CH2Cl2/MeOH 20:1). To a solution of this derivative (70 mg, 0.038
mmol) in MeOH/THF (2:1, 300 íL) was added KCN (2 mg, 0.031
mmol). After stirring at room temperature for 10 h, the solvent was
removed and the crude was purified by column chromatography on
silica gel (CH2Cl2/MeOH, 20:1) to give the deacetylated derivative 17
(36 mg, 58%). Rf ) 0.44 (CH2Cl2/MeOH 10:1). 1H NMR (500.13 MHz,
CD3OD): ä 7.75 (d, J ) 8 Hz, 2H, O-Ts), 7.36 (d, J ) 8 Hz, 2H,
O-Ts), 7.4-7.2 (m, 30H, CH2Ph), 5.24 (broad s, 1H, H1I), 5.01 (broad
s, 1H, H1III), 5.2-5.0 (12H, CH2Ph), 4.81 (broad s, 1H, H1IV), 1.97
(m, 1H, H2II equatorial), 1.65-1.60 (m, 4H, -CH2-CH2-CH2-OTs),
1.36 (m, 1H, H2II axial). 13C NMR (75.47 MHz, CD3OD): 130-129
(CH2Ph), 111.6 (C1III), 100.6 (C1IV), 100.5 (C1I), 69-68, (CH2Ph),
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35.4 (C2II), 30.8 (-CH2-CH2-CH2-OTs), 26.5(-CH2-CH2-CH2-
OTs), 86.8, 82.5, 81.9, 76.3, 73.7, 73.3, 72.2, 69.5, 68.4, 57.8, 54.6,
52.8, 52.5, 43.5, 42.6. MALDI-TOF m/z 1623.3 [M + Na+].
Compound 3. Treatment of 17 (12 mg, 0.0075 mmol) under the
same conditions described for the preparation of compound 9 gave the
fully deprotected tosilate (5 mg, 88%) which was used in the next step
without further purification. Rf ) 0.16 (NH4OH/CHCl3/nBuOH/EtOH,
3:1:2:2.5). A diluted solution of this compound (5 mg, 0.0066 mmol)
in H2O (100 mL, pH 7.0) was stirred at 40 °C for 10 days. The solvent
was removed at reduced pressure, and the crude was purified by ion
exchange column chromatography (0.5 cm  7 cm) with Amberlite
CG-50 (0-7.5% NH4OH) to give, after lyophilization, compound 3 (3
mg, 62%). Rf ) 0.16 (NH4OH/CHCl3/n-BuOH/EtOH 3:1:2:2.5). 1H
NMR (500.13 MHz, D2O): 5.9 (d, J ) 3.9 Hz, 1H, H1I), 5.5 (d, J )
3.5 Hz, 1H, H1III), 5.2 (d, J ) 1.5 Hz, 1H, H1IV), 4.3 (1H, H2III), 4.2
(1H, H4III), 3.6 (1H, H2IV), 3.6 (1H, H7III), 3.5 (1H, H2I), 3.1 (1H,
H7III), 2.5 (m, 1H, H2II equatorial), 2.3 (1H, H5III), 2.1 (1H, H6III), 1.8
(m, 1H, H2II axial), 1.7 (1H, H5III), 1.7 (1H, H6III). 13C NMR (75.47
MHz, D2O): 108.7 (C1III), 96.4 (C1I), 96.1 (C1IV), 73.2 (C2III), 59.3
(C2I), 50.8 (C2IV), 49.8 (C7III), 31.3 (C5III), 28.2 (C2II), 21.8 (C6III).
MALDI-TOF m/z 648.1 [M + Na+].
Compound 6. Palladium on charcoal (1:5 catalyst/substrate by
weight) was added to a solution of 17 (25 mg, 0.016 mmol) and
trifluoroacetic acid (20 íL, 0.26 mmol) in MeOH (3 mL). After stirring
the suspension under H2 (1 atm) at room temperature for 48 h, the
catalyst was removed by filtration, and the solvent was evaporated at
reduced pressure. Derivative 6 (6.3 mg, 0.010 mmol) was purified by
ion exchange column chromatography (0.5 cm  7 cm) with Amberlite
CG-50 (0-7.5% NH4OH); yield: 60%. Rf ) 0.24 (NH4OH/CHCl3/
nBuOH/EtOH, 3:1:2:2.5). 1H NMR (500.13 MHz, D2O ): ä 5.9 (broad
s,1H, H1I), 5.3 (d, J ) 3.5 Hz, 1H, H1III), 5.2 (broad s, 1H, H1IV), 4.3
(1H, H2III), 3.5 (1H, H2IV), 3.4 (1H, H6I), 3.4 (1H, H6IV), 3.4 (1H,
H6IV), 3.3 (1H, H2I), 3.2 (1H, H6I), 2.3 (m, 1H, H2II equatorial), 1.7
(m, 1H, H2II axial). 13C NMR (75.47 MHz, D2O): 109.7 (C1III), 95.7
(C1IV), 95.1(C1I), 79.4 (C2III), 53.5 (C2 I), 50.9 (C2IV), 40.5 (C6IV),
40.2 (C6I), 29.7 (C2II). MALDI-TOF m/z 649.8 [M + Na+].
NMR and Molecular Modeling of 2-4. RESP atomic charges for
neomycin-B analogues 2-4 were derived by applying the RESP module
of the AMBER 5.0 package26 to the HF/6-31G(d) ESP charges
calculated with Gaussian-94.38 All MD simulations were carried
out using the SANDER module within AMBER and the Cornell et al.
force field.39 Parameters for the acetalic functions were taken from
GLYCAM.40
NMR Structure of Derivatives 2-4. NMR experiments were
recorded on a Varian Unity 500 and Bruker Avance 500 at 313 K.
Selective 1D NOE experiments were recorded employing the 1D-
DPFGSE NOE pulse sequence. NOE intensities were normalized with
respect to the diagonal peak at zero mixing time. Selective T1
measurements were performed on the anomeric and several other
protons to obtain the above-mentioned values. Experimental NOEs were
fitted to a double exponential function, f(t) ) p0(e-p1t)(1 - e-p2t) with
p0, p1, and p2 being adjustable parameters.41 The initial slope was
determined from the first derivative at time t ) 0, f ′(0) ) p0p2. From
the initial slopes, interproton distances were obtained by employing
the isolated spin pair approximation.
To obtain a NMR-derived ensemble, MD-tar25 simulations were
performed for compounds 2-4 employing a protocol identical to that
described by Asensio et al.16 NOE-derived distances were included as
time averaged distance constraints, and scalar coupling constants, as
time averaged J coupling constraints. A 〈r-6〉-1/6 average was used for
the distances, and a linear average was used for the coupling constants.
For derivatives 2 and 4, final trajectories were carried out using explicit
solvent, counterions, periodic boundary conditions (PBC) and Ewald
sums for the treatment of electrostatic interactions. An exponential decay
constant of 500 ps and simulation lengths of 5 ns were employed.
For compound 3, the experimental data could only be quantitatively
reproduced after (in vacuo  ) 80) 80 ns MD-tar simulations.
Preliminary tests showed that, for this flexible molecule, the use of
exponential decay constants shorter than 5 ns produced unstable
trajectories and led in some cases to severe distortions of the sugar
rings. This problem could be solved by increasing the exponential decay
constant value to 8-10 ns. It has been estimated that simulation lengths
of ca. 1 order of magnitude larger than the exponential decay constant
should be used to generate reliable estimates of average properties.
Therefore the final simulation length used was 80 ns. We would like
to point out that for MD-tar runs the sensitivity of the results to the
simulation conditions (solvent, counterions, cutoffs, dielectric constant,
etc.) used is extremely dependent on the amount of experimental
information included as time-averaged constraints. For derivative 3 we
employed 23 distance constraints and 7 J values. Under these conditions,
the conformational regions sampled by the trajectory (within the
esterically allowable regions) are mainly determined by the constraints,
and the fine details of the simulation are not critical. In fact similar
results were obtained using  ) 40 and  ) 20.
Finally, to further clarify the conformational properties of 3, we
performed additional calculations. Thus, a geometry representative of
each of the five most populated conformational families present for
derivative 3 in solution, according to the in vacuo  ) 80 MD-tar
calculations, was subjected to 5 ns unconstrained MD simulations in
the presence of explicit water, counterions, periodic boundary condi-
tions, and Ewald sums for the treatment of electrostatic interactions.
The obtained trajectories show that, as deduced from the in vacuo MD-
tar simulations, the macrocyclic structure of compound 3 is compatible
with wide fluctuations around the glycosidic linkages, different
puckerings for ring III and different orientations for the three methylene
bridge. In fact, the conformational regions populated by 3 according
to these simulations are similar those deduced from the in vacuo 80 ns
MD-tar trajectories (Figure S7).
Binding Experiments. The labeled 27mer A-site model was obtained
in its polyacrylamide gel electrophoresis- (PAGE-) purified sodium salt
form from Dharmacon Research, Inc. (Lafayette, CO). Buffer conditions
for the binding experiments were 100 mM NaCl, 10 mM sodium
phosphate (pH 7.6). Fluorescence experiments were conducted on a
Fluorolog-3 spectrophotometer (Jobin Yvon-Spex Instruments S.A.,
Inc., New Jersey) equipped with a thermostat. A quartz cell with a 1
cm path length in both the excitation and emission directions was used
in all the experiments that were performed at 25 °C. The RNA
concentration was, in all cases, 1 íM in strand. For renaturing the RNA,
it was placed in a water bath at 20 °C, heated to 85 °C for 1 min and
then slowly cooled back to 20 °C over a 2 h period. With the excitation
wavelength set to 310 nm, the change in the fluorescence emission at
369 nm upon complex formation was followed in titration experiments.
Aliquots of the antibiotic derivatives were added sequentially, and 2
min of equilibration time were allowed before each fluorescence
measurement. Fluorescence intensities were corrected for volume
changes according to the following equation: Fi,corr ) Fi,obs*Vi/Vo where
Fi,corr is the corrected intensity for point i of the titration, Fi,obs is the
measured intensity at point i, Vi is the volume after the ith addition and
Vo is the initial volume (typically 2 mL). The Kd values for simple
binding were determined by plotting Fi,corr against the ligand to RNA
ratio. In all cases, the data were found to fit well assuming a 1:1
complex.
Cloning, Overexpression, and Purification of the Aminoglyside
Modifying Enzymes. The plasmid codifying for the AAC(2′)-Ic from
Mycobacterium tuberculosis was kindly provided by J. S. Blanchard
(38) Pople, J. A. et al. Gaussian-94; Gaussian, Inc.: Pittsburgh, PA, 1995.
(39) Cornell, W. D.; Cieplack, P. C.; Bayly, I.; Gould, I. R.; Merz, K.; Ferguson,
D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. J. Am.
Chem. Soc. 1995, 117, 5179-5197.
(40) Woods, R. J.; Dwek, R. A.; Edge, C. J.; Fraser-Reid, D. J. Phys. Chem.
1995, 99, 3832-3839.
(41) Haselhorst, T.; Weimar, T.; Peters, T. J. Am. Chem. Soc. 2001, 123, 10705-
10714.
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(Albert Einstein College of Medicine, New York). This plasmid was
transformed in the E. coli strain BL21(DE3). The expression and
purification of Mycobacterium tuberculosis AAC(2′) was performed
as described by J. S. Blanchard and co.42
Enterococcus faecalis APH(3′) and Staphylococcus aureus ANT(4′)
were subcloned from the plasmids pACYC177 and pBBR1MCS-2,
respectively. PCR amplifications were performed in a 100 íL reaction
mixture containing DNA (3 íL) of the plasmids as a template, water
(70.5 íL), buffer (100 mM Tris-HCL, 500 mM KCl, pH 8.0, 10 íL),
MgCl2 (2 mM, 8íL), dNTPs (200 íM), primers (1 íM), and Taq DNA
polymerase (2.5 U). The primers employed for Enterococcus faecalis
APH(3′) were Nt (NdeI) (5’tataacatatgagccatattcaaggg3′) and Ct (EcoR
I)- (5’ttatagaattcttagaaaaactcatc3′), and those used for Staphylococcus
aureus ANT(4′) were Nt(Hind III)(5′gccgcaagattctgaatggaccaataata3′)
and Ct(Xho I) (5′gcctcgagtcaaaatggtatgcgttt3′). The reaction was
subjected to 30 cycles of amplification. The cycle conditions were set
as follows: denaturation at 94 °C for 1 min, annealing at 50 °C/1.0
min for Enterococcus faecalis APH(3′), and 55 °C/1.0 min for
Staphylococcus aureus ANT(4′) and elongation at 72 °C for 1 min.
The genes obtained from the PCR were purified with the Wizard PCR
Preps DNA Purification System (Promega) and ligated in pET-28b(+).
The pET28b-APH3′ and pET28b-ANT4′ expression vectors constructed
in this way were then transformed into E. coli BL21(DE3) competent
cells.
Selected clones for Enterococcus faecalis APH(3′) and Staphylo-
coccus aureus ANT(4′) were grown on 100 mL of LB medium
containing 26 íg/mL kanamycin at 37 °C. When the cell growth reached
an optical density at 600 nm (OD600) of 0.5, the temperature was
switched to 30 °C and the culture was induced with 0.5 mm IPTG.
After 24 h of induction, the expression level was analyzed by SDS-
PAGE using gels with 13% polyacrylamide in the separation zone.
Proteins were purified employing a Ni2+-IDA-agarose column. The
enzymes after this step were found to be more than 90% pure as
assessed by SDS-polyacrylamide gel electrophoresis.
Enzymatic Activity. Enzymatic reactions were performed in NMR
tubes. The nucleoside triphosphate (ATP 100 íM-3.0 mM) and the
aminoglycoside (100 íM-1.5 mM) were dissolved in 10 mM phosphate
buffer, pH 7.0, 2.5-5.0 mM MgCl2. After addition of the enzyme (0.2-
20 íM), the evolution of the reaction mixture at 37 °C was monitored
by 1D 1H NMR, and the final products were characterized by 2D NMR
and MALDI-TOF MS.
Biological Activity. Minimal inhibitory concentrations (MIC) were
measured according to a published method.43 The different bacteria
were grown in 1 mL of Mueller-Hinton broth to an optical density
OD600 of 0.5 units. The desired concentrations of antibiotic were added
from stock solutions. The samples were incubated at 37 °C for 24 h.
After this time the control culture (with no antibiotic) had an OD600 of
1.2-1.6. Then the OD600 of each sample was read, and the MIC was
taken as the lowest antibiotic concentration inhibiting bacterial growth
by greater than 90%.
To determine the effect that expression of AAC(2′) has on the MIC
values the previously described protocol was slightly modified. The
different bacteria were grown in 1 mL of Mueller-Hinton broth to an
optical density OD600 of 0.3 units. The temperature was switched to
30 °C, and the culture was induced with 0.5 mm IPTG. When the OD600
reached 0.5 units, the desired concentrations of antibiotic were added
from stock solutions. The samples were incubated at 30 °C for 24 h,
and the MIC was taken as the lowest antibiotic concentration inhibiting
bacterial growth by greater than 90%.
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